This page shows the latest Alexion Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, has received approval from the US Food and Drug Administration (FDA) for its long-acting C5 complement inhibitor, Ultomiris (ravulizumab-cwvz). ... Marc Dunoyer, CEO, Alexion, commented: “Ultomiris,
programme. The manufacturing plant project – developed with the support and collaboration of Ireland’s investment agency, IDA Ireland – will be located at the Alexion Campus in College Park, Dublin. ... AstraZeneca completed its $39bn takeover of
Alexion purchase looks increasingly ‘copper-bottomed’ as AstraZeneca prepares to submit data for ALXN1840 in Wilson disease. ... AstraZeneca’s new rare disease unit, formed through the $39bn purchase of Alexion Pharmaceuticals, had announced
Elliott Management is viewed as an ‘aggressive activist’ investor – in the pharma industry, the hedge fund petitioned for the sale of Alexion Pharmaceuticals ahead of its subsequent acquisition by AstraZeneca in
Following the planned completion of the separation, due in mid-2022, GSK will remain solely focused on pharmaceuticals and vaccine products. ... Elliott Management is known to be an ‘aggressive activist’ investor – in the pharma industry, the hedge
AZ has also excluded its proposed acquisition of Alexion Pharmaceuticals from this guidance, adding in the Q1 results that Alexion will become its rare disease unit and an ‘area of expertise’. ... Sustained pipeline progress and accelerating business
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options. ... 100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Sarin will become AZ's new chief financial officer upon closing of the company’s acquisition of Alexion Pharmaceuticals. ... AstraZeneca (AZ) has appointed Aradhana Sarin (pictured above) as its new chief financial officer and an executive director
Prior to CRISPR, he worked as head of translational medicine at Alexion Pharmaceuticals, and also served as chief medical officer of Taligen Therapeutics. ... Cagnoni, chief executive officer of Rubius. Titan Pharmaceuticals. Kate DeVarney has joined
He joins the company from Aegerion Pharmaceuticals. Amryt Pharma, a company focused on treatments for rare and orphan diseases, has appointed Jordi Casals as the biopharma’s head of Europe. ... Prior to this, he worked for eight years at Alexion
Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of
Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel. ... Meanwhile, Valles-Sukkar arrives
More from appointments
Approximately 1 fully matching, plus 9 partially matching documents found.
They include: Aerogen, Akcea, Allakos, Alexion, Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer, Biocryst, Biogen, Biomarin, Bio-Oil, Boehringer Ingelheim, Cryoport, Colgate Palmolive, CSL Behring, Eiger BioPharmaceuticals, EIT Health,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...